Pioneering in Drug Development Empowering Tomorrow's Health with Innovation
Novelwise Pharmaceutical Corporation

Company Profile

Novelwise Pharmaceutical Corporation was formerly the New Drug Research and Development Department of NatureWise Biotech & Medicals Corporation. We have over 20 years of experience in new drug development, including basic research, clinical translation, and strategic planning. As our new drug development projects reached significant milestones, the R&D Department was established as a separate entity in 2023 to expedite its progress. With rigorous in-house research and strategic partnerships, we aim to address unmet medical needs by developing innovative therapeutics. Building on this solid foundation, Novelwise Pharma is expanding into RNA interference (RNAi) technology. RNAi offers high specificity in regulating a broader range of disease-causing genes, making it a novel strategy for next-generation medical treatment. Our operations focus on preclinical research, advancing clinical trials, technology licensing, and strategic partnerships. By integrating the product pipelines of new chemical entities and RNA interference therapeutics, we aim to deliver a next-generation solution for cancer treatment. The dual-engine strategy enhances the depth and breadth of our portfolio, positioning Novelwise Pharma as a high-value and globally competitive provider of therapeutics.

Business Strategy

Research-Driven Innovation

Innovating therapies to meet today's unmet medical needs

Leveraging our in-depth independent research capabilities, we actively engage in collaboration with academic communities to explore niche markets and identify promising target products. We formulate the optimal development strategy for drug candidates through a comprehensive assessment of market dynamics, regulatory frameworks, and scientific research findings. By developing innovative drugs, we hope to provide solutions with exceptional efficacy, safety, and patient convenience to meet unmet medical needs.

Focused Innovation in High-Value Targeted Therapies

We are dedicated to precision medicine and high-value, targeted therapies, utilizing innovative technologies to streamline processes and enhance drug development efficiency, thereby increasing the success of commercialization

Agile R&D Through Early Integration and Intelligent Decision-Making

By incorporating preclinical data and clinical insights early, we maintain a flexible R&D approach that reduces development risks and enables rapid adaptation to market changes.

Strategic Collaboration and Resource Integration

We actively foster cross-sector collaboration, forming strategic alliances with academia, biotech companies, CROs, regulatory agencies, and global pharmaceutical partners. These partnerships strengthen our internal R&D capabilities and accelerate innovation.

Market-Driven Prioritization and Differentiated Development

We prioritize high-potential projects, craft differentiated development strategies with strong commercial potential, and build lasting competitive advantages to drive sustainable growth.

R&D

NBM-BMX : Specific HDAC8 Inhibitor

NBM-BMX is a novel chemical entity designed to selectively inhibit histone deacetylase 8 (HDAC8). While non-selective HDAC inhibitors face limitations in clinical applications due to significant side effects, the development of isoform-selective inhibitors like NBM-BMX offers a promising alternative. NBM-BMX has demonstrated potent anti-proliferative effects across various cancer cell types, particularly in tumors with elevated HDAC8 expression. Novelwise Pharmaceutical holds the global rights for the research, manufacturing, and commercialization of NBM-BMX. The drug shows strong market potential for newly diagnosed ....

Proceed to Form

Pioneering in Drug Development Empowering Tomorrow's Health with InnovationNovelwise Pharmaceutical Corporation